Ganciclovir for CMV Pulmonary Infection
For CMV pulmonary infection, intravenous ganciclovir at 5 mg/kg every 12 hours for 14-21 days is the treatment of choice, followed by maintenance therapy if the patient remains immunocompromised. 1
Dosing Strategy
Induction Therapy
- Standard dose: 5 mg/kg IV every 12 hours, infused over 1-2 hours
- Duration: 14-21 days for tissue-invasive CMV disease (including pulmonary infection) 1, 2
- Administration: Must be given intravenously; oral ganciclovir capsules should NOT be used for induction treatment 3
The KDIGO guidelines specifically recommend that all patients with serious tissue-invasive CMV disease (which includes pulmonary infection) be treated with intravenous ganciclovir 2. This is particularly critical because CMV pneumonitis carries significant mortality risk in immunocompromised patients.
Maintenance Therapy
After completing induction, maintenance therapy depends on the underlying condition:
- HIV-infected patients: Lifelong maintenance with 5 mg/kg/day IV or transition to oral valganciclovir 900 mg daily 1
- Transplant recipients: Continue until CMV is no longer detectable by plasma PCR or pp65 antigenemia 2
Renal Dose Adjustments
Critical caveat: Ganciclovir requires mandatory dose adjustment for renal impairment 3:
- CrCl ≥70 mL/min: 5 mg/kg every 12 hours
- CrCl 50-69 mL/min: 2.5 mg/kg every 12 hours
- CrCl 25-49 mL/min: 2.5 mg/kg every 24 hours
- CrCl 10-24 mL/min: 1.25 mg/kg every 24 hours
- CrCl <10 mL/min: 1.25 mg/kg three times weekly (post-hemodialysis)
Monitoring Requirements
Hematologic Monitoring
Monitor complete blood counts and platelets frequently - myelosuppression is the major dose-limiting toxicity 1:
- Neutropenia occurs in 18-25% of patients 3
- Dose reduction or interruption necessary in up to 40% due to hematologic toxicity 1
- Do not administer if ANC <500/µL or platelets <25,000/µL 3
- Consider G-CSF for severe neutropenia 1
Renal Monitoring
- Monitor serum creatinine closely - renal toxicity can occur 1
- Adjust doses promptly for declining renal function
Virologic Monitoring
- Weekly CMV viral load monitoring (by PCR or pp65 antigenemia) during treatment 2
- Continue therapy until CMV is no longer detectable 2
Alternative Agents
If ganciclovir cannot be used:
Foscarnet is the primary alternative 1:
- Dose: 60 mg/kg IV every 8 hours for 14-21 days
- Infuse over 1-2 hours (no faster than 1 mg/kg/minute)
- Major toxicity: Nephrotoxicity (30% develop elevated creatinine) and electrolyte abnormalities
- Requires saline hydration and close electrolyte monitoring
- May have survival advantage over ganciclovir in some HIV patients 1
Maribavir can be considered for resistant/refractory cases 4, 5:
- Not recommended as first-line for pulmonary CMV
- Poor CNS/eye penetration limits use
- Reserve for ganciclovir-resistant infections
Special Populations
Transplant Recipients
- Reduce immunosuppression in life-threatening CMV disease or persistent disease despite treatment 2
- Monitor graft function closely during CMV treatment 2
Pediatric Patients
- Same dosing: 5 mg/kg IV every 12 hours 1
- All CMV disease in pediatric transplant recipients should be treated with IV ganciclovir (not oral valganciclovir) 2
Common Pitfalls to Avoid
Never use oral ganciclovir or valganciclovir for induction treatment of CMV pneumonitis - bioavailability is inadequate for serious tissue-invasive disease 3
Don't forget renal dose adjustments - failure to adjust leads to severe myelosuppression 3
Avoid premature discontinuation - continue until viral clearance documented, not just clinical improvement 2
Watch for drug resistance - emerges after several weeks of therapy, particularly with suboptimal dosing 1
Monitor for thrombophlebitis - ganciclovir is irritating to veins; consider central access for prolonged therapy 1